Across TCGA pan-cancer cohorts, SLC25A32 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC25A32 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC25A32 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A32 expression acts as an unfavorable survival marker.
LUAD are the cancer types where SLC25A32 Mutation most reproducibly stratifies survival.